Antibodies targeting these two proteins showed notable bone anabolic effects in rat and primate osteoporotic models (Fulciniti et al, 2009; Ominsky et al, 2010), and sclerostin antibodies are currently under clinical trials as anti‐osteoporosis agents (Ferrari, 2014). The gene discussed is SOST; the disease is osteoporosis.